These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26662361)

  • 1. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
    Gold R; Phillips JT; Havrdova E; Bar-Or A; Kappos L; Kim N; Thullen T; Valencia P; Oliva L; Novas M; Li J; Sweetser MT; Kurukulasuriya N; Viglietta V; Fox RJ
    Neurol Ther; 2015 Dec; 4(2):93-104. PubMed ID: 26662361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry.
    Hellwig K; Rog D; McGuigan C; Houtchens MK; Bruen DR; Mokliatchouk O; Branco F; Peng X; Everage NJ
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34815321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.
    Gold R; Stefoski D; Selmaj K; Havrdova E; Hurst C; Holman J; Tornesi B; Akella S; McCroskery P
    Neurol Ther; 2016 Dec; 5(2):169-182. PubMed ID: 27411694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports.
    Mahadevan U; Levy G; Gensler L; Ali M; Lacerda AP; Wegrzyn L; Palac H; Bhutani-Jacques T; Long M; Clowse MEB; Kimball AB; Chambers C; Scialli AR
    Drug Saf; 2024 Oct; 47(10):1039-1049. PubMed ID: 39008024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
    O'Gorman J; Russell HK; Li J; Phillips G; Kurukulasuriya NC; Viglietta V
    Clin Ther; 2015 Jul; 37(7):1402-1419.e5. PubMed ID: 25999183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry.
    Hellwig K; Rog D; McGuigan C; Houtchens MK; Bruen DR; Mokliatchouk O; Branco F; Levin S; Everage N; Lin X
    Mult Scler; 2024 Feb; 30(2):209-215. PubMed ID: 38166480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.
    Fox RJ; Gold R; Phillips JT; Okwuokenye M; Zhang A; Marantz JL
    Neurol Ther; 2017 Dec; 6(2):175-187. PubMed ID: 28770420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
    Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Marantz JL
    Neurol Ther; 2016 Jun; 5(1):45-57. PubMed ID: 26932146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Allan M; Grant L
    Neurol Ther; 2020 Jun; 9(1):85-92. PubMed ID: 31834566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data.
    Hoeltzenbein M; Beck E; Rajwanshi R; Gøtestam Skorpen C; Berber E; Schaefer C; Østensen M
    Semin Arthritis Rheum; 2016 Oct; 46(2):238-245. PubMed ID: 27346577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy.
    Landi D; Bartolomeo S; Bovis F; Amato MP; Bonavita S; Borriello G; Buccafusca M; Bucello S; Cavalla P; Cellerino M; Centonze D; Cocco E; Conte A; Cortese A; D'Amico E; Di Filippo M; Docimo R; Fantozzi R; Ferraro E; Filippi M; Foschi M; Gallo A; Granella F; Ianniello A; Lanzillo R; Lorefice L; Lucchini M; Lus G; Mataluni G; Mirabella M; Moiola L; Napoli F; Nicoletti CG; Patti F; Ragonese P; Realmuto S; Schirò G; Signoriello E; Sinisi L; Stromillo ML; Tomassini V; Vecchio D; Sormani MP; Marfia GA
    Mult Scler; 2024 Oct; 30(11-12):1503-1513. PubMed ID: 39263885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.